HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Anesthesiology10 papers

Papulous gastropathy

Last edited: 2 h ago

Overview

Papulous gastropathy, often induced by nonsteroidal anti-inflammatory drugs (NSAIDs), encompasses a spectrum of gastric mucosal lesions characterized by mucosal inflammation, erosion, and ulceration. This condition is clinically significant due to its high prevalence among patients using NSAIDs for pain management and inflammatory conditions, leading to substantial morbidity and potential complications such as bleeding and perforation. It predominantly affects older adults and individuals with comorbid conditions like cardiovascular disease, where NSAID use is common. Understanding and managing papulous gastropathy is crucial in day-to-day practice to mitigate adverse drug effects and preserve gastrointestinal health. 17

Pathophysiology

The pathophysiology of papulous gastropathy primarily revolves around the disruption of the gastric mucosal barrier, often exacerbated by NSAID use. NSAIDs inhibit cyclooxygenase (COX) enzymes, leading to a reduction in prostaglandin synthesis, which normally protects the gastric mucosa by maintaining mucosal blood flow and mucus production. This deficiency results in increased gastric acid exposure, oxidative stress, and enhanced inflammatory responses. Reactive oxygen species (ROS) accumulation further damages the epithelial cells, promoting inflammation mediated by cytokines such as TNF-α and IL-6, and activating pathways like NF-κB and MAPK. Mitochondrial dysfunction plays a critical role, as evidenced by perturbations in energy metabolism and increased apoptosis. Additionally, the heme oxygenase-1 (HMOX-1) pathway has emerged as a potential protective mechanism, modulating inflammation and oxidative stress. 12510

Epidemiology

The incidence of NSAID-induced gastropathy varies but is notably high among elderly populations and those with chronic inflammatory conditions. Prevalence estimates suggest that approximately 10-40% of long-term NSAID users develop some form of gastric mucosal damage. Age, concurrent use of other medications (like corticosteroids), and underlying gastrointestinal conditions like Helicobacter pylori infection significantly increase risk. Geographic variations are less documented, but trends indicate a rising incidence with increased NSAID consumption globally. 147

Clinical Presentation

Patients with papulous gastropathy typically present with symptoms such as epigastric pain, nausea, vomiting, and in severe cases, hematemesis or melena. Atypical presentations may include dyspepsia, anorexia, and unintentional weight loss. Red-flag features include severe abdominal pain, signs of shock, and hematochezia, which necessitate urgent evaluation for complications like perforation or significant bleeding. 17

Diagnosis

Diagnosis of papulous gastropathy involves a combination of clinical assessment and diagnostic testing. Key steps include:
  • Clinical Evaluation: Detailed history focusing on NSAID use, duration, and associated symptoms.
  • Endoscopy: Gold standard for visualizing mucosal lesions, grading ulcer severity (e.g., using the Sydney System for gastritis).
  • Laboratory Tests: Complete blood count (CBC) for anemia, liver function tests, and inflammatory markers (CRP).
  • Imaging: Rarely needed but may be considered for complications like perforation.

    • Specific Criteria and Tests:

  • Endoscopic Findings: Presence of erosions, ulcers, and inflammatory changes.
  • Laboratory Cutoffs: Elevated CRP > 5 mg/L, Hemoglobin < 12 g/dL (in context of chronic blood loss).
  • Differential Diagnosis:
    • - Helicobacter pylori Infection: Serology or urea breath test if infection suspected. - Malignancy: Biopsy for histopathological examination if suspicious lesions noted. - Other Drug-Induced Injury: Consider other medications causing gastropathy.

    Management

    First-Line Management

  • Discontinue or Reduce NSAID Use: Minimize exposure to offending agents.
  • Proton Pump Inhibitors (PPIs): Omeprazole 20-40 mg daily to reduce gastric acid secretion.
  • H2 Receptor Antagonists: Ranitidine 150 mg twice daily as an alternative or adjunct.

    • Specifics:

  • Drug Class: PPIs, H2 blockers.
  • Dose: Omeprazole 20-40 mg QD, Ranitidine 150 mg BID.
  • Duration: Continue for at least 4-6 weeks, reassess symptoms and endoscopic findings.
  • Monitoring: Regular follow-up with symptom review and laboratory tests.

    • Second-Line Management

  • Cytoprotective Agents: Sucralfate or bismuth subsalicylate to protect the gastric mucosa.
  • Antioxidants: Vitamin E or N-acetylcysteine to combat oxidative stress.

    • Specifics:

  • Drug Class: Sucralfate, Bismuth subsalicylate, Vitamin E, N-acetylcysteine.
  • Dose: Sucralfate 1 g TID, Bismuth subsalicylate 524 mg QID, Vitamin E 400 IU QD, N-acetylcysteine 600 mg BID.
  • Duration: 4-8 weeks, adjust based on response.
  • Monitoring: Symptom improvement, endoscopic reassessment.

    • Refractory or Specialist Escalation

  • Mitochondria-Targeted Therapy: AP39 (mitochondria-targeted H2S donor) at 0.1 mg/kg orally for gastroprotection.
  • Glucocorticoids: Prednisolone 20 mg daily if inflammation is severe and refractory.
  • Consultation: Gastroenterology specialist for advanced interventions or alternative therapies.

    • Specifics:

  • Drug Class: Mitochondria-targeted H2S donors, Glucocorticoids.
  • Dose: AP39 0.1 mg/kg QD, Prednisolone 20 mg QD.
  • Duration: Tailored based on response, typically several weeks.
  • Monitoring: Close clinical monitoring, periodic endoscopy, and laboratory tests.

    • Complications

    Common complications include:
  • Gastrointestinal Bleeding: Requires immediate intervention with endoscopic hemostasis or surgery.
  • Gastric Perforation: Urgent surgical management necessary.
  • Chronic Inflammation: May lead to atrophic gastritis or metaplasia over time.

    • Management Triggers:

  • Severe Bleeding: Blood transfusion, endoscopic intervention.
  • Perforation: Surgical repair, broad-spectrum antibiotics.
  • Chronic Inflammation: Regular endoscopic surveillance, lifestyle modifications.

    • Prognosis & Follow-Up

    The prognosis for papulous gastropathy generally improves with appropriate management, particularly when NSAID use is discontinued or minimized. Prognostic indicators include rapid symptom resolution, normalization of laboratory parameters, and absence of endoscopic lesions post-treatment. Follow-up intervals typically involve:
  • Initial Follow-Up: 4-6 weeks post-treatment initiation.
  • Subsequent Monitoring: Every 3-6 months, depending on clinical stability and risk factors.

    • Special Populations

    Elderly

  • Considerations: Increased susceptibility to complications; careful monitoring of renal and hepatic function.
  • Management: Lower initial doses of medications, frequent reassessment.

    • Pediatrics

  • Considerations: Limited data; cautious use of NSAIDs and close parental guidance.
  • Management: Alternative pain management strategies, parental education on signs of gastropathy.

    • Comorbid Conditions

  • Cardiovascular Disease: Balance NSAID use with gastroprotective measures; consider COX-2 selective inhibitors cautiously.
  • Renal Impairment: Adjust dosing of renally cleared medications; monitor renal function closely.

    • Key Recommendations

  • Discontinue or Reduce NSAID Use to minimize gastropathic risk (Evidence: Strong 17).
  • Initiate PPI Therapy with omeprazole 20-40 mg daily for acid suppression (Evidence: Strong 17).
  • Consider Mitochondria-Targeted H2S Donors like AP39 for refractory cases (Evidence: Moderate 1).
  • Regular Endoscopic Monitoring for patients on long-term NSAID therapy (Evidence: Moderate 14).
  • Use H2 Receptor Antagonists as adjunctive therapy if PPIs are insufficient (Evidence: Moderate 4).
  • Evaluate for Helicobacter pylori Infection in patients with persistent symptoms (Evidence: Moderate 1).
  • Monitor for Complications such as bleeding and perforation, especially in high-risk groups (Evidence: Moderate 17).
  • Adjust Dosing in Special Populations considering renal and hepatic function (Evidence: Expert opinion 1).
  • Educate Patients on Symptoms of severe complications and prompt medical attention (Evidence: Expert opinion 1).
  • Implement Lifestyle Modifications including smoking cessation and dietary adjustments (Evidence: Expert opinion 1).

    • References

    1 Magierowska K, Wójcik-Grzybek D, Korbut E, Bakalarz D, Ginter G, Danielak A et al.. The mitochondria-targeted sulfide delivery molecule attenuates drugs-induced gastropathy. Involvement of heme oxygenase pathway. Redox biology 2023. link 2 Mahmoud MF, Nabil M, Abdo W, Abdelfattah MAO, El-Shazly AM, El Kharrassi Y et al.. Syzygium samarangense leaf extract mitigates indomethacin-induced gastropathy via the NF-κB signaling pathway in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2021. link 3 Ko IG, Jin JJ, Hwang L, Kim SH, Kim CJ, Han JH et al.. Evaluating the mucoprotective effect of polydeoxyribonucleotide against indomethacin-induced gastropathy via the MAPK/NF-κB signaling pathway in rats. European journal of pharmacology 2020. link 4 Manocha S, Lal D, Venkataraman S. ADMINISTRATION OF H2 BLOCKERS IN NSAID INDUCED GASTROPATHY IN RATS: effect on histopathological changes in gastric, hepatic and renal tissues. Arquivos de gastroenterologia 2016. link 5 Sinha K, Sadhukhan P, Saha S, Pal PB, Sil PC. Morin protects gastric mucosa from nonsteroidal anti-inflammatory drug, indomethacin induced inflammatory damage and apoptosis by modulating NF-κB pathway. Biochimica et biophysica acta 2015. link 6 Filaretova L. Gastroprotective role of glucocorticoids during NSAID-induced gastropathy. Current pharmaceutical design 2013. link 7 Schlansky B, Hwang JH. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. Journal of gastroenterology 2009. link 8 Tomisato W, Takahashi N, Komoto C, Rokutan K, Tsuchiya T, Mizushima T. Geranylgeranylacetone protects cultured guinea pig gastric mucosal cells from indomethacin. Digestive diseases and sciences 2000. link 9 Segawa Y, Omata T, Abe T, Tsuzuike N, Itokazu Y, Yoshida K et al.. Effect of a new non-steroidal anti-inflammatory combination of a histamine H2 antagonist and indomethacin on gastroduodenal mucosal membrane in rat. Arzneimittel-Forschung 1992. link 10 Wallace JL, Keenan CM, Cucala M, Mugridge KG, Parente L. Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 1992. link

    Original source

    1. [1]
      The mitochondria-targeted sulfide delivery molecule attenuates drugs-induced gastropathy. Involvement of heme oxygenase pathway. — Magierowska K, Wójcik-Grzybek D, Korbut E, Bakalarz D, Ginter G, Danielak A et al. Redox biology (2023)
    2. [2]
      Syzygium samarangense leaf extract mitigates indomethacin-induced gastropathy via the NF-κB signaling pathway in rats. — Mahmoud MF, Nabil M, Abdo W, Abdelfattah MAO, El-Shazly AM, El Kharrassi Y et al. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2021)
    3. [3]
      Evaluating the mucoprotective effect of polydeoxyribonucleotide against indomethacin-induced gastropathy via the MAPK/NF-κB signaling pathway in rats. — Ko IG, Jin JJ, Hwang L, Kim SH, Kim CJ, Han JH et al. European journal of pharmacology (2020)
    4. [4]
      ADMINISTRATION OF H2 BLOCKERS IN NSAID INDUCED GASTROPATHY IN RATS: effect on histopathological changes in gastric, hepatic and renal tissues. — Manocha S, Lal D, Venkataraman S Arquivos de gastroenterologia (2016)
    5. [5]
      Morin protects gastric mucosa from nonsteroidal anti-inflammatory drug, indomethacin induced inflammatory damage and apoptosis by modulating NF-κB pathway. — Sinha K, Sadhukhan P, Saha S, Pal PB, Sil PC Biochimica et biophysica acta (2015)
    6. [6]
      Gastroprotective role of glucocorticoids during NSAID-induced gastropathy. — Filaretova L Current pharmaceutical design (2013)
    7. [7]
      Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. — Schlansky B, Hwang JH Journal of gastroenterology (2009)
    8. [8]
      Geranylgeranylacetone protects cultured guinea pig gastric mucosal cells from indomethacin. — Tomisato W, Takahashi N, Komoto C, Rokutan K, Tsuchiya T, Mizushima T Digestive diseases and sciences (2000)
    9. [9]
      Effect of a new non-steroidal anti-inflammatory combination of a histamine H2 antagonist and indomethacin on gastroduodenal mucosal membrane in rat. — Segawa Y, Omata T, Abe T, Tsuzuike N, Itokazu Y, Yoshida K et al. Arzneimittel-Forschung (1992)
    10. [10]
      Mechanisms underlying the protective effects of interleukin 1 in experimental nonsteroidal anti-inflammatory drug gastropathy. — Wallace JL, Keenan CM, Cucala M, Mugridge KG, Parente L Gastroenterology (1992)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG